Spyre Therapeutics Surges 23.4% After SPY001 Phase 2 Delivers 9.2-Point RHI Drop
Spyre Therapeutics reported Phase 2 SKYLINE trial for SPY001 achieved its primary endpoint with a 9.2-point reduction in the Robart's Histopathology Index and 40% clinical remission. Deutsche Bank raised its price target to $88, driving a 23.36% stock surge and lifting market capitalization to about $3.82 billion.
1. Phase 2 SKYLINE Trial Results
Spyre Therapeutics' Phase 2 SKYLINE trial of SPY001 met its primary endpoint with a 9.2-point reduction in the Robart's Histopathology Index at week 12. Secondary endpoints included a 40% clinical remission rate and 51% endoscopic improvement, with the drug showing a clean safety profile.
2. Analyst Raises Price Target
Deutsche Bank increased its price target on Spyre Therapeutics from $55 to $88, implying a 39.1% upside. The revision reflects confidence in SPY001's best-in-class potential and its role in treating moderate-to-severe ulcerative colitis.
3. Stock Surge and Market Valuation
Following the trial update and target hike, Spyre Therapeutics shares jumped 23.36% and reached a 52-week high. The company's market capitalization rose to approximately $3.82 billion, underscoring robust investor sentiment.